Jim Martineau
Jim is the co-founder/CEO of Nosis Bio, an AI-enabled biotech focused on the design and development of cell-specific RNA medicines. Jim has worked for over 15 years at the intersection of precision medicine and machine learning. Most recently, Jim was Head of Oncology Product at Natera (NASDAQ: NTRA) where he was responsible for leading advanced diagnostics including Signatera, the leading Molecular Residual Disease test for early relapse detection in solid tumors. Prior to Natera, Jim worked at Roche and Flatiron Health building a clinico-genomics data platform to accelerate late stage oncology clinical development. Jim earned a MSc from Stanford in Computational & Mathematical Engineering as well as MBA from the Wharton School in Healthcare Management and BSc in Engineering Physics from Colorado School of Mines.
Nosis Bio
Designing Cellular Medicines: Using High-Throughput Experiments and AI Approaches to Program Cells to Cure Disease
-
We now live in a world where genetically engineered cells are circulating people's bodies and warding off cancer. But the first approved cell-based medicines—such as CAR-T therapy—are just the beginning. In this session, we'll explore the next generation of programmable cellular medicines.
